Hepatitis C Virus and Antiviral Drug Resistance by 源��듅�깮 et al.
Review
Gut and Liver, Vol. 10, No. 6, November 2016, pp. 890-895
Since its discovery in 1989, hepatitis C virus (HCV) has 
been intensively investigated to understand its biology and 
develop effective antiviral therapies. The efforts of the previ-
ous 25 years have resulted in a better understanding of the 
virus, and this was facilitated by the development of in vitro 
cell culture systems for HCV replication. Antiviral treatments 
and sustained virological responses have also improved 
from the early interferon monotherapy to the current all-oral 
regimens using direct-acting antivirals. However, antiviral 
resistance has become a critical issue in the treatment of 
chronic hepatitis C, similar to other chronic viral infections, 
and retreatment options following treatment failure have be-
come important questions. Despite the clinical challenges in 
the management of chronic hepatitis C, substantial progress 
has been made in understanding HCV, which may facilitate 
the investigation of other closely related flaviviruses and lead 
to the development of antiviral agents against these human 
pathogens. (Gut Liver 2016;10:890-895)
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INTRODUCTION
Hepatitis C virus (HCV) infects approximately 130 to 170 
million people worldwide and the infected patients suffer from 
chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Most 
of HCV infection (70% to 80%) becomes chronic and has been a 
tremendous burden on the public health. The HCV infection was 
first known as non-A, non-B hepatitis (NANBH)1,2 and the caus-
ative agent of this NANBH was identified as hepatitis C virus 
in 1989.3 Since then, substantial progresses in the knowledge 
of HCV virology, development of research tools, and drug dis-
covery have been made and now new antiviral therapies based 
on all-oral regimens are beginning to be used. A few notable 
accomplishments in HCV virology include the development of 
replicon system4 and JFH1 cell culture-infectious clone,5 which 
enabled screening of small molecule libraries for drug discovery 
as well as investigating all the steps of HCV life cycle including 
virus assembly and secretion. 
VIROLOGY
HCV is an enveloped, positive-strand RNA virus and belongs 
to the genus Hepacivirus within the family Flaviviridae (for a 
comprehensive review of HCV virology, see Lemon et al.6). The 
RNA genome of this virus is approximately 9.6 kb long and 
encodes a single polyprotein by the internal ribosome entry 
site-dependent translation (Fig. 1). The polyprotein (~3,000 
amino acids) is co- and post-translationally processed by both 
virus and host proteases to generate a total of 10 viral proteins 
(N terminus-Core-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-
NS5B-C terminus). The three proteins (Core, E1, and E2) at the 
N terminus are the structural proteins that are directly involved 
in the formation of virions while the rest at the C terminus (p7, 
NS2, NS3, NS4A, NS4B, NS5A, and NS5B) are the nonstructural 
proteins. Briefly, the core protein is a component of viral capsid 
and E1, E2 proteins are envelope glycoproteins that mediate the 
hepatocyte-specific entry of HCV virions. Nonstructural proteins 
are involved in many aspects of HCV life cycle including viral 
genome replication. p7 protein is known as an ion channel 
protein (viroporin) and NS2 protein is a cysteine autoprotease, 
which catalyzes the cleavage between NS2 and NS3 protein. 
Both p7 and NS2 proteins are also known to be involved in 
virus assembly process. The proteins from NS3 to NS5B (NS3-
NS4A-NS4B-NS5A-NS5B) are indispensable for viral RNA rep-
lication as the major components of the replication complex.4 
NS3 protein contains two enzymatic activities: serine protease 
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and helicase. The protease activity of NS3 cleaves the viral pro-
teins of the polyprotein from NS3 to NS5B, while the helicase 
activity is involved in viral assembly. NS4A protein is a cofactor 
of NS3 protein and helps NS3 protein associate with the cellular 
membrane. NS4B protein is known to generate membranous 
web structures near the ER membrane of the host cell, which 
are thought to be the place where RNA replication occurs. NS5A 
protein does not have any known enzymatic activity but is 
important for both viral RNA replication and infectious virus 
assembly. Finally, NS5B is an RNA-dependent RNA polymerase 
that synthesizes plus- and minus-strand of viral RNAs. Among 
these viral proteins, NS3, NS5A, and NS5B proteins are the 
major targets of direct-acting antivirals (DAAs) and currently 
several DAAs are being used for treatment of chronic hepatitis C 
(Fig. 1).
1. Virus life cycle
Overall, the life cycle of HCV is similar to those of other posi-
tive-strand RNA viruses. The virus enters the hepatocyte via the 
receptor-mediated endocytosis (for an updated, comprehensive 
review of HCV entry, see Ding et al.7). After fusion and uncoat-
ing of the virion within the cell, the viral genome is released 
into the cytoplasm. Since the viral genome is positive-sense, it 
is directly used as mRNA for translation of the viral polyprotein. 
Several viral proteins (NS3 to NS5B) after cleavage and process-
ing of the viral polyprotein are recruited to the membranous 
web to make replication complexes. Within this replication 
complex, the viral genome replication occurs (for an updated, 
comprehensive review of HCV RNA replication and assembly, 
see Paul et al.8): a negative-strand RNA is synthesized first using 
the positive-strand viral RNA and then multiple copies of posi-
tive-strand RNA are synthesized using the negative-strand viral 
RNA. The structural proteins and the positive-strand viral RNA 
are then assembled to produce infectious virus particles near the 
lipid droplets9 and the infectious virus particles are released out 
of the cell using the host VLDL-secretory pathway.10,11 
2. Systems for studying HCV
Development of in vitro cell culture system for HCV replica-
tion is indispensable for HCV research and drug discovery. The 
first replicon system, that supports HCV genome replication 
when its RNA is transfected into the Huh7 hepatoma cells, was 
reported in 1999.4 This replicon system used the genotype 1b 
Con1 isolate and currently the replicon systems are available 
for most of the HCV genotypes.12-18 While the replicon system 
is useful for studying viral genome replication, it does not sup-
port the production of infectious virus particles. In 2003, the 
functional HCV pseudoparticle system (HCVpp) was described.19 
The virus that is produced by this system is in fact a retrovirus, 
but is coated with HCV envelope glycoproteins, E1 and E2, thus 
the infection by the HCVpp generally follows the steps of the 
specific HCV entry pathway. By incorporating the sequence of 
reporter genes such as green fluorescent protein or luciferase, 
the virus entry can be monitored either visually or quantita-
tively without further complications due to the viral genome 
replication. Finally, the first cell culture-infectious clone (HCVcc), 
which can recapitulate the entire viral life cycle of HCV in cell 
culture, was established in 2005 using the genotype 2a JFH1 
isolate.5 This virus was unique in that its RNA was able to 
replicate efficiently in Huh7 hepatoma cells without any cell 
culture-adaptive mutations, which were indispensable for other 
replicons to replicate in the in vitro cell culture system. When 
the JFH1 RNA was transfected into the Huh7 hepatoma cells, 
the transfected cells supported the production of infectious virus 
particles as well as the efficient RNA replication. The produced 
virus particles could then infect animal models such as chim-
panzee and naïve hepatoma cells, thus completing an entire vi-
ral life cycle. This system can be used for investigation of all the 
steps of viral life cycle, specifically virus assembly and secretion 
steps. The HCVcc system is currently available for the genotypes 
1a, 2a, and 3a.5,20-23
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Fig. 1. Hepatitis C virus genome 
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TREATMENT OF CHRONIC HEPATITIS C
Since the description of NANBH, treatment of chronic hepa-
titis C has evolved from the nonspecific antiviral treatment 
using interferon to the all-oral regimens using DAAs.24 In the 
late 1990s, the interferon monotherapy for the treatment of 
chronic hepatitis C patients was modified by the addition of 
ribavirin, a nucleoside analog, which increased the sustained 
virological response (SVR) by 20% compared to the interferon 
monotherapy.25 And later, pegylation of interferon (pegIFN) was 
demonstrated more effective than nonpegylated interferon by 
an increase of SVR of 10% to 15%.26,27 Thus, until very recently, 
the administration of pegIFNα and ribavirin for 6 to 12 months 
had been the standard of care before using DAAs. During this 
evolution of treatment options, the SVR rates have increased 
from the 15% to 20%28,29 by the IFNα monotherapy to over 90% 
by the DAA treatments. 
The first DAAs, which were approved in 2011 for use in the 
treatment of chronic hepatitis C, were boceprevir (Merck) and 
telaprevir (Vertex), both NS3 protease inhibitors. These DAAs 
were not used by themselves, but used with pegIFNα and 
ribavirin as triple therapy due to the occurrence of resistant 
mutations. Despite some toxicity issues, an improved SVR of 
approximately 75% was achieved by this therapy for genotype 
1 HCV-infected patients.30,31 Since the approval of these NS3 
protease inhibitors for the treatment of chronic hepatitis C, more 
DAAs have been approved and are still being tested in clinical 
trials. Currently, three different viral proteins (NS3, NS5A, and 
NS5B) are the major targets of DAAs and interferon-free, all-
oral regimens are expected to be the standard of care in most of 
chronic hepatitis C treatments due to the severe side effects and 
poor tolerability of interferon treatment. However, antiviral drug 
resistance has become an issue again as was experienced in the 
treatment of other chronic viral diseases. From in vivo and in 
vitro data, the profiles of various resistant mutations against the 
DAA treatments have already been well documented (Fig. 2).32 
Currently, most of DAA therapies are dual or triple therapy 
combining DAAs from different classes with or without ribavi-
rin in order to minimize the occurrence of resistant mutations. 
1. NS3 
NS3 protein has two known enzymatic activities: serine 
protease and helicase. Most of DAAs targeting this protein act 
as protease inhibitors. Thus, one main mechanism of action of 
this class of DAAs is inhibition of proteolytic cleavage of viral 
proteins from NS3 to NS5B, which eventually suppresses viral 
RNA replication. Among the currently available NS3-targeting 
DAAs, boceprevir and telaprevir were approved for clinical use 
for the first time, which were followed by simeprevir, asunapre-
vir, and paritaprevir. Several antiviral-resistant mutations are 
frequently observed, for example, at V36, V55, R155, and D168 
of NS3 protein (Table 1, Fig. 2). Interestingly, when the viral fit-
ness of the resistant mutations was assessed using the in vitro 
cell culture system, many resistant mutations showed defects 
in viral RNA replication while some (e.g., R155T) showed more 
severe defects in infectious virus production,33 thus suggesting a 
potential role of NS3 protease in virus assembly. 
2. NS5A 
NS5A protein has no known enzymatic activity but is impor-
NS3 protease (180 amino acids)
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Fig. 2. Antiviral-resistant mutations of NS3 protease, NS5A and NS5B RNA-dependent RNA polymerase. The resistance-associated amino acids 
are located with the corresponding direct-acting antivirals that select these resistances: NS3 (B, boceprevir; T, telaprevir; S, simeprevir; A, asuna-
previr; P, paritaprevir; and V, vaniprevir), NS5A (D, daclatasvir; L, ledipasvir; and O, ombitasvir) and NS5B (S, sofosbuvir; D, dasabuvir; and B, 
beclabuvir). Note that sofosbuvir is a nucleotide inhibitor, whereas dasabuvir and beclabuvir are nonnucleoside inhibitors.
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tant for both viral RNA replication and assembly of infectious 
virus particles. NS5A protein is composed of an N-terminal 
amphipathic α-helix that associates with the cellular membrane 
and three consecutive domains (domain 1 to 3). The domains 1 
and 2 are important for viral RNA replication while the domain 
3 is indispensable for virus assembly.34-37 Daclatasvir (Bristol-
Myers Squibb), the first NS5A-targeting DAA, was discovered 
during the small molecule library screening using the genotype 
1b Con1 replicon cell line.38 The inhibitory potency of dacla-
tasvir was outstanding but this inhibitor also selected resistant 
mutations such as Y93H and L31V (Fig. 2). In fact, the presence 
of these resistant mutations is known as the key determinant 
of the success of daclatasvir + asunaprevir dual therapy.39 In 
the presence of these mutations, the SVR for the daclatasvir + 
asunaprevir dual therapy was less than 50%.39 So far, all known 
resistant mutations of NS5A were identified in the domain 1 
(Table 2, Fig. 2). A recent kinetic analysis of DAAs from the dif-
ferent classes found that NS5A inhibitors restrict two distinct 
steps of HCV life cycle: replication complex formation and virus 
assembly.40 Interestingly, NS5A protein exists as a dimer, which 
is also suggested by the symmetrical structure of daclatasvir.41 
3. NS5B 
NS5B protein is an RNA-dependent RNA polymerase, a key 
enzyme which directly catalyzes the synthesis of plus- and 
minus-strand of viral RNAs. This protein is a highly error-prone 
enzyme since it does not have the proofreading capability. De-
pending on the inhibition modes, NS5B inhibitors are classified 
into either nucleotide analogs (e.g., sofosbuvir) or nonnucleo-
side analogs (e.g., dasabuvir, beclabuvir), the latter of which act 
as allosteric inhibitors. Of these inhibitors, sofosbuvir (Gilead) 
is particularly interesting in that it showed excellent SVRs in 
numerous clinical trials and a very high genetic barrier to re-
sistance development. This unique property of sofosbuvir has 
made it the first choice of DAA for several all-oral regimens for 
treatment of chronic hepatitis C. Despite its outstanding profiles 
as an antiviral agent, the cost is still an issue in many countries. 
Several resistance-associated mutations of NS5B are located in 
Fig. 2 and the most commonly observed NS5B resistant muta-
tions are summarized in Table 3. Interestingly, no cross-resis-
tance was observed between the nucleotide and nonnucleoside 
inhibitors due to the different mechanisms and sites of interac-
tion with NS5B.
CONCLUSIONS
Substantial progresses in the development of antiviral thera-
pies have increased the sustained virological response and now 
approximately 90% to 95% of chronic hepatitis C patients are 
expected to be cured, thus significantly reducing the number of 
more complicating liver diseases such as cirrhosis and hepato-
cellular carcinoma. Although this is a remarkable accomplish-
ment and the first in the human history in that the chronic viral 
infection is curable, still the 5% to 10% of the chronic hepatitis 
C patients are suffering from this viral infection and awaiting 
better treatment options. In addition, more cases of antiviral 
drug resistance are being reported and the retreatment of the 
patients who have failed in the prior antiviral treatments is the 
issue that has to be immediately addressed. 
In terms of virology, HCV was discovered relatively later 
than the other closely related viruses belonging to the family 
Flaviviridae (e.g., dengue virus, Japanese encephalitis virus, 
Table 1. Most Commonly Observed NS3-Resistant Mutations32 
Inhibitor Genotype 1a Genotype 1b
Boceprevir V36M, T54S, R155K T54A/S, V55A, A156S, V170A
Telaprevir V36M, R155K V36A, T54A, A156S
Simeprevir R155K, D168E/V Q80R, D168E/V
Asunaprevir R155K, D168E D168E/V/Y
Paritaprevir D168A/V/Y Y56H, D168V
Vaniprevir R155K, D168T/V/Y D168H/T/V
Table 2. Most Commonly Observed NS5A-Resistant Mutations32
Inhibitor Genotype 1a Genotype 1b
Daclatasvir M28T, Q30E/H/R, L31M, H58D, Y93H/N L31M/V, Y93H
Ledipasvir Q30E/R, L31M, Y93C/H/N Y93H
Ombitasvir M28T, Q30R Y93H
Table 3. Most Commonly Observed NS5B-Resistant Mutations32
Inhibitor Genotype 1a Genotype 1b
Dasabuvir M414T, S556G S556G
Baclabuvir A421V, P495L/S None
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West Nile virus, yellow fever virus, etc.). However, the signifi-
cant global impact of HCV infection has far more advanced 
virology of this specific virus and the knowledge that was 
obtained from the study of HCV would accelerate a better un-
derstanding of the other clinically important flaviviruses. In 
addition, it would also lead to the development of new antiviral 
therapies to eradicate these deadly human pathogens.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
REFERENCES
1. Alter HJ, Holland PV, Morrow AG, Purcell RH, Feinstone SM, 
Moritsugu Y. Clinical and serological analysis of transfusion-
associated hepatitis. Lancet 1975;2:838-841. 
2. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. 
Transfusion-associated hepatitis not due to viral hepatitis type A 
or B. N Engl J Med 1975;292:767-770. 
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton 
M. Isolation of a cDNA clone derived from a blood-borne non-A, 
non-B viral hepatitis genome. Science 1989;244:359-362. 
4. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager 
R. Replication of subgenomic hepatitis C virus RNAs in a hepa-
toma cell line. Science 1999;285:110-113. 
5. Wakita T, Pietschmann T, Kato T, et al. Production of infectious 
hepatitis C virus in tissue culture from a cloned viral genome. Nat 
Med 2005;11:791-796.
6. Lemon SM, Walker CM, Alter MJ, Yi M. Hepatitis C virus. In: 
Knipe DM, Howley PM, Griffin DE, et al, eds. Fields virology. 
Volume 1. 5th ed. Philadelphia: Lippincott Williams and Wilkins, 
2007:1253-1304.
7. Ding Q, von Schaewen M, Ploss A. The impact of hepatitis C virus 
entry on viral tropism. Cell Host Microbe 2014;16:562-568. 
8. Paul D, Madan V, Bartenschlager R. Hepatitis C virus RNA replica-
tion and assembly: living on the fat of the land. Cell Host Microbe 
2014;16:569-579.
9. Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an 
important organelle for hepatitis C virus production. Nat Cell Biol 
2007;9:1089-1097.
10. Huang H, Sun F, Owen DM, et al. Hepatitis C virus production by 
human hepatocytes dependent on assembly and secretion of very 
low-density lipoproteins. Proc Natl Acad Sci U S A 2007;104:5848-
5853.
11. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. 
Cellular determinants of hepatitis C virus assembly, maturation, 
degradation, and secretion. J Virol 2008;82:2120-2129.
12. Yi M, Lemon SM. Adaptive mutations producing efficient replica-
tion of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J 
Virol 2004;78:7904-7915. 
13. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV 
RNA replication in cell culture. Science 2000;290:1972-1974.
14. Saeed M, Scheel TK, Gottwein JM, et al. Efficient replication of 
genotype 3a and 4a hepatitis C virus replicons in human hepa-
toma cells. Antimicrob Agents Chemother 2012;56:5365-5373.
15. Saeed M, Gondeau C, Hmwe S, et al. Replication of hepatitis C vi-
rus genotype 3a in cultured cells. Gastroenterology 2013;144:56-
58.e7.
16. Peng B, Yu M, Xu S, et al. Development of robust hepatitis C virus 
genotype 4 subgenomic replicons. Gastroenterology 2013;144:59-
61.e6.
17. Wose Kinge CN, Espiritu C, Prabdial-Sing N, Sithebe NP, Saeed M, 
Rice CM. Hepatitis C virus genotype 5a subgenomic replicons for 
evaluation of direct-acting antiviral agents. Antimicrob Agents 
Chemother 2014;58:5386-5394.
18. Yu M, Peng B, Chan K, et al. Robust and persistent replication of 
the genotype 6a hepatitis C virus replicon in cell culture. Antimi-
crob Agents Chemother 2014;58:2638-2646.
19. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus 
pseudo-particles containing functional E1-E2 envelope protein 
complexes. J Exp Med 2003;197:633-642.
20. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Produc-
tion of infectious genotype 1a hepatitis C virus (Hutchinson strain) 
in cultured human hepatoma cells. Proc Natl Acad Sci U S A 
2006;103:2310-2315.
21. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh 
J. Highly efficient full-length hepatitis C virus genotype 1 
(strain TN) infectious culture system. Proc Natl Acad Sci U S A 
2012;109:19757-19762. 
22. Yamane D, McGivern DR, Wauthier E, et al. Regulation of the 
hepatitis C virus RNA replicase by endogenous lipid peroxidation. 
Nat Med 2014;20:927-935.
23. Kim S, Date T, Yokokawa H, et al. Development of hepatitis C 
virus genotype 3a cell culture system. Hepatology 2014;60:1838-
1850.
24. Heim MH. 25 Years of interferon-based treatment of chronic hepa-
titis C: an epoch coming to an end. Nat Rev Immunol 2013;13:535-
542.
25. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-
2b alone or in combination with ribavirin as initial treatment for 
chronic hepatitis C: Hepatitis Interventional Therapy Group. N 
Engl J Med 1998;339:1485-1492. 
26. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-
2b plus ribavirin compared with interferon alfa-2b plus ribavirin 
for initial treatment of chronic hepatitis C: a randomised trial. 
Lancet 2001;358:958-965.
27. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a 
plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 
2002;347:975-982.
28. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon 
alfa-2b for chronic hepatitis C: effects of dose increment and du-
ration of treatment on response rates: results of the first multicen-
Kim S, et al: Hepatitis C Virus and Antiviral Drug Resistance  895
tre Australian trial. Australia Hepatitis C Study Group. J Hepatol 
1995;23:487-496. 
29. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three 
interferon alfa-2b regimens for the long-term treatment of chronic 
non-A, non-B hepatitis: Multicenter Study Group. N Engl J Med 
1995;332:1457-1462.
30. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated 
chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-
1206.
31. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for 
previously untreated chronic hepatitis C virus infection. N Engl J 
Med 2011;364:2405-2416.
32. Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug 
resistance-associated substitutions: state of the art summary. 
Hepatology 2015;62:1623-1632.
33. Shimakami T, Welsch C, Yamane D, et al. Protease inhibitor-resis-
tant hepatitis C virus mutants with reduced fitness from impaired 
production of infectious virus. Gastroenterology 2011;140:667-
675. 
34. Appel N, Zayas M, Miller S, et al. Essential role of domain III of 
nonstructural protein 5A for hepatitis C virus infectious particle 
assembly. PLoS Pathog 2008;4:e1000035.
35. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C 
virion production via phosphorylation of the NS5A protein. PLoS 
Pathog 2008;4:e1000032.
36. Masaki T, Suzuki R, Murakami K, et al. Interaction of hepatitis C 
virus nonstructural protein 5A with core protein is critical for the 
production of infectious virus particles. J Virol 2008;82:7964-
7976.
37. Kim S, Welsch C, Yi M, Lemon SM. Regulation of the production 
of infectious genotype 1a hepatitis C virus by NS5A domain III. J 
Virol 2011;85:6645-6656.
38. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy 
identifies an HCV NS5A inhibitor with a potent clinical effect. Na-
ture 2010;465:96-100.
39. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic 
escape in hepatitis C virus genotype 1b patients treated with the 
direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 
2013;58:646-654.
40. McGivern DR, Masaki T, Williford S, et al. Kinetic analyses reveal 
potent and early blockade of hepatitis C virus assembly by NS5A 
inhibitors. Gastroenterology 2014;147:453-462.e7.
41. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-
binding domain of an essential component of the hepatitis C virus 
replicase. Nature 2005;435:374-379. 
